drugset
drugset / Trial / NCT03596294

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

NCT03596294 ↗

Phase 1 Completed 14 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

A study in healthy male subjects to investigate whether administration of rifampicin can affect the fate in the body (amount and time of presence in the blood) of clazosentan

Timeline

Start
2018-07-19
Primary completion
2018-08-03
Completion
2018-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clazosentan Small molecule 15 mg Intravenous
Subject Rifampicin Small molecule 600 mg Intravenous

Indications

No indication recorded.